Anthrax toxin: a tripartite lethal combination
FEBS letters, 2002 Anthrax is a severe bacterial infection that occurs when Bacillus anthracis spores gain access into the body and germinate in macrophages, causing septicemia and toxemia.
VISCA P +5 more
core +7 more sources
Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors. [PDF]
PLoS ONE, 2011 Anthrax toxin is the major virulence factor produced by Bacillus anthracis. The toxin consists of three protein subunits: protective antigen (PA), lethal factor, and edema factor.
Chenguang Cai +8 more
doaj +1 more source
Evidence against a human cell-specific role for LRP6 in anthrax toxin entry. [PDF]
PLoS ONE, 2008 The role of the cellular protein LRP6 in anthrax toxin entry is controversial. Previous studies showed that LRP6 was important for efficient intoxication of human M2182 prostate carcinoma cells but other studies performed with cells from gene-knockout ...
Patricia L Ryan, John A T Young
doaj +1 more source
A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines. [PDF]
PLoS ONE, 2016 Several different human vaccines are available to protect against anthrax. We compared the human adaptive immune responses generated by three different anthrax vaccines or by previous exposure to cutaneous anthrax.
Thomas R Laws +14 more
doaj +1 more source
Disulfide bonds in the ectodomain of anthrax toxin receptor 2 are required for the receptor-bound protective-antigen pore to function. [PDF]
PLoS ONE, 2010 Cell-surface receptors play essential roles in anthrax toxin action by providing the toxin with a high-affinity anchor and self-assembly site on the plasma membrane, mediating the toxin entry into cells through endocytosis, and shifting the pH threshold ...
Jianjun Sun, R John Collier
doaj +1 more source
Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment. [PDF]
PLoS ONE, 2012 Soluble receptor decoy inhibitors, including receptor-immunogloubulin (Ig) fusion proteins, have shown promise as candidate anthrax toxin therapeutics.
Diane Thomas +5 more
doaj +1 more source
Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein. [PDF]
PLoS ONE, 2009 BACKGROUND:To initiate infection, Bacillus anthracis needs to overcome the host innate immune system. Anthrax toxin, a major virulence factor of B. anthracis, impairs both the innate and adaptive immune systems and is important in the establishment of ...
Haijing Hu, Stephen H Leppla
doaj +1 more source
Designed Azolopyridinium Salts Block Protective Antigen Pores In Vitro and Protect Cells from Anthrax Toxin [PDF]
, 2013 Background:Several intracellular acting bacterial protein toxins of the AB-type, which are known to enter cells by endocytosis, are shown to produce channels.
Barth, Holger +24 more
core +2 more sources
Anthrax Susceptibility: Human Genetic Polymorphisms Modulating ANTXR2 Expression
Toxins, 2015 Anthrax toxin causes anthrax pathogenesis and expression levels of ANTXR2 (anthrax toxin receptor 2) are strongly correlated with anthrax toxin susceptibility.
Zhang Zhang +11 more
doaj +1 more source
Three rare cases of anthrax arising from the same source [PDF]
, 2006 Anthrax is an acute bacterial infection caused by Bacillus anthracis. Humans become infected under natural conditions by contact with infected animals or contaminated animal products.
Ashrafi, G +7 more
core +1 more source